Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Marilyn K. Glassberg"'
Autor:
Lisa Villarroel, Erin Tams, Luke Smith, Jessica Rigler, Dena Wilson, Chengcheng Hu, Marilyn K. Glassberg
Publikováno v:
Frontiers in Public Health, Vol 10 (2023)
IntroductionThe Arizona Surge Line was an emergent initiative during the COVID-19 pandemic to facilitate COVID-19 patient transfers and load-level hospitals on a statewide level. It was designed and implemented by the Arizona Department of Health Ser
Externí odkaz:
https://doaj.org/article/e3073ae857124d6a859a478256fb2d2d
Autor:
Giacomo Lanzoni, Elina Linetsky, Diego Correa, Shari Messinger Cayetano, Roger A. Alvarez, Dimitrios Kouroupis, Ana Alvarez Gil, Raffaella Poggioli, Phillip Ruiz, Antonio C. Marttos, Khemraj Hirani, Crystal A. Bell, Halina Kusack, Lisa Rafkin, David Baidal, Andrew Pastewski, Kunal Gawri, Clarissa Leñero, Alejandro M. A. Mantero, Sarah W. Metalonis, Xiaojing Wang, Luis Roque, Burlett Masters, Norma S. Kenyon, Enrique Ginzburg, Xiumin Xu, Jianming Tan, Arnold I. Caplan, Marilyn K. Glassberg, Rodolfo Alejandro, Camillo Ricordi
Publikováno v:
Stem Cells Translational Medicine, Vol 10, Iss 5, Pp 660-673 (2021)
Abstract Acute respiratory distress syndrome (ARDS) in COVID‐19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti‐inflammatory effects and could yield beneficial effects in COVID‐19 ARDS. The
Externí odkaz:
https://doaj.org/article/9d1fa9e738bc472aab4a9772e4e11f97
Autor:
Ian Glaspole, Francesco Bonella, Elena Bargagli, Marilyn K. Glassberg, Fabian Caro, Wibke Stansen, Manuel Quaresma, Leticia Orsatti, Elisabeth Bendstrup
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Idiopathic pulmonary fibrosis (IPF) predominantly affects individuals aged > 60 years who have several comorbidities. Nintedanib is an approved treatment for IPF, which reduces the rate of decline in forced vital capacity (FVC). W
Externí odkaz:
https://doaj.org/article/57038a9eca7d4d9a964fc3f324dec3b2
Autor:
Leticia Kawano-Dourado, Marilyn K. Glassberg, Deborah Assayag, Raphaël Borie, Kerri A. Johannson
Publikováno v:
European Respiratory Review, Vol 30, Iss 162 (2021)
Sex and gender differences influence key domains of research, lung health, healthcare access and healthcare delivery. In interstitial lung diseases (ILDs), mouse models of pulmonary fibrosis are clearly influenced by sex hormones. Additionally, short
Externí odkaz:
https://doaj.org/article/01735e73dae640f79e148ec99fa602ce
Autor:
Ulrich Costabel, Carlo Albera, Marilyn K. Glassberg, Lisa H. Lancaster, Wim A. Wuyts, Ute Petzinger, Frank Gilberg, Klaus-Uwe Kirchgaessler, Paul W. Noble
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-4 (2019)
Abstract Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These explorat
Externí odkaz:
https://doaj.org/article/7d687304dbbb497eba5dcba3618502f1
Publikováno v:
Frontiers in Medicine, Vol 7 (2021)
Externí odkaz:
https://doaj.org/article/90698cc77674453db3e09bb3ad7c91ff
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline. A great deal of enthusiasm has been generated for the use of these drugs, which are by n
Externí odkaz:
https://doaj.org/article/e90eed3ac42a4e2b9873d0fcdc92eda8
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
The novel coronavirus (COVID-19) has continued its global spread since the first documented case in late 2019 in Wuhan, China. With over 10 million cases and 500 thousand deaths reported worldwide, the need for an effective treatment regimen is evide
Externí odkaz:
https://doaj.org/article/4168e16ef00745928ed3ee525c1b7bfa
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in t
Externí odkaz:
https://doaj.org/article/e5032a21e8c948afadbb1a023916faed
Autor:
Argyrios Tzouvelekis, Rebecca Toonkel, Theodoros Karampitsakos, Kantha Medapalli, Ioanna Ninou, Vasilis Aidinis, Demosthenes Bouros, Marilyn K. Glassberg
Publikováno v:
Frontiers in Medicine, Vol 5 (2018)
Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown origin. Prognosis is poor, with limited treatment options available, and the median survival remains just 3–5 years. Despite the use of pirfenidone and ninteda
Externí odkaz:
https://doaj.org/article/ee1ea4a1d915443bac0962b4b307a3f9